SET and neoplasm: To explore the therapeutic potential for PP2A activation through SET inhibition as an approach for NSCLC therapy, we treated NSCLC cells with FTY720 and measured tumor growth and oncogenic potential in vitro and in vivo. Consistent with the demonstrated ability of FTY720 suppresses tumor growth; we observed that FTY720 treatment resulted in decreased proliferation and colony formation in vitro.